| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC3576 |
| Trial ID | NCT06022744 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | LX109 |
| Recruitment status | Not Recruiting |
| Title | An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) |
| Year | 2023 |
| Country | China |
| Company sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Other ID(s) | SHGH-LX109 |
| Vector information | |||||||
|
|||||||
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||